Charleston, Daiichi hydrocodone product pact worth up to $650m
This article was originally published in Scrip
Executive Summary
Daiichi Sankyo will pay Jupiter, Florida-based Charleston Laboratories $100m up front, a $100m near-term milestone fee and up to $450m for future regulatory and approval milestone under a collaboration to develop and commercialize fixed-dose combination (FDC) hydrocodone products in the US.